Skip to main content

Day: June 22, 2020

The Addax and Oryx Group PLC and Zeg Oil and Gas Ltd. Announce Definitive Agreement for Zeg to Acquire Control of Oryx Petroleum Corporation Limited

ST. JULIANS, Malta and ROAD TOWN, British Virgin Islands, June 22, 2020 (GLOBE NEWSWIRE) — AOG Upstream B.V. (“AOG”), an indirect wholly-owned subsidiary of The Addax and Oryx Group PLC, and Zeg Oil and Gas Ltd. (“Zeg”) announced today that they have entered into an agreement (the “Purchase Agreement”) which provides for the acquisition by Zeg, and the disposition by AOG and certain of its affiliates, of an aggregate of 380,527,641 common shares (the “Acquired Shares”) in the capital of Oryx Petroleum Corporation Limited (the “Issuer”) for an aggregate purchase price of approximately US$16.4 million (approximately C$22.4 million) or approximately US$0.043 per Acquired Share (approximately C$0.058).Immediately prior to entering into the Purchase Agreement, Zeg owned 119,625,033 common shares in the capital of the Issuer (“Shares”),...

Continue reading

Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

— XPOVIO is Now the Only Single-Agent, Oral Therapy Approved for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma, Including DLBCL Arising from Follicular Lymphoma —— XPOVIO is the First and Only FDA-Approved Drug for Use in Both Multiple Myeloma and DLBCL —— Conference Call Scheduled for Today at 12:30 p.m. Eastern Time —NEWTON, Mass., June 22, 2020 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved oral XPOVIO® (selinexor), the Company’s first-in-class, Selective Inhibitor of Nuclear Export (SINE) compound, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified,...

Continue reading

Coronary Stent Market to Reach USD 8.08 Billion by 2027; Increasing Regulatory Approvals Will Provide Impetus to Market Growth, says Fortune Business Insights™

Pune, June 22, 2020 (GLOBE NEWSWIRE) — The global Coronary Stent Market size is projected to reach USD 8.08 billion by the end of 2027. High investment in technological intervention has opened up a huge potential for market growth. According to a report published by Fortune Business Insights, titled “Coronary Stent Market Size, Share & Industry Analysis, By Stent Type (Drug-Eluting Stent, Bioresorbable Stent, Bare Metal Stent, Covered Stent, Others), By Deployment (Self-expandable, Balloon-expandable), By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics, Others) and Regional Forecast, 2020-2027,” the market was worth USD 5.91 billion in 2019 and will exhibit a CAGR of 6.7% during the forecast period, 2020-2027.Technological advancements in these products have helped improve surgical procedures and subsequently...

Continue reading

DSV, 833 – Trading update for Q2 2020

Company Announcement No. 833The COVID-19 crisis continues to impact the global transport and logistics markets negatively, however, we are now able to provide an update on the expected results for Q2 2020. Based on the market development, progress of the Panalpina integration and other cost measures, we expect EBIT before special items for Q2 2020 above DKK 2,300 million (Q1 2020: 1,566 million DKK).Jens Bjorn Andersen, Group CEO: ”The quarter has developed better than we anticipated when the COVID-19 crisis started. This illustrates the strength of our business model and the skills of the DSV staff, who have been working hard to create solutions for our customers in unprecedented and difficult markets. At the same time, we have benefitted from the continued integration of Panalpina and the cost savings initiative we announced earlier...

Continue reading

Truxton Trust Adds William Benson as Private Banking Vice President

NASHVILLE, Tenn., June 22, 2020 (GLOBE NEWSWIRE) — Truxton Trust Company announced that William A. Benson has joined the firm as Vice President, Private Banking. Mr. Benson has over ten years’ experience in banking in Nashville, having worked in Private Banking and Healthcare Lending at two area banks.  Mr. Benson earned his Bachelor of Business Administration from The University of Georgia Terry College of Business.  He is active in the community and is currently an Ambassador for the Vanderbilt-Ingram Cancer Center and a Young Alumni Board Member and Alumni Board Member at Montgomery Bell Academy and The Ensworth School, respectively.    “William’s diverse banking background, work ethic, and focus on client service make him a wonderful addition to our Private Banking team as our business continues to grow” said Tom Stumb, Chairman...

Continue reading

Verizon completes successful Dynamic Spectrum Sharing Technology trials in Advance of 5G Nationwide

BASKING RIDGE, N.J., June 22, 2020 (GLOBE NEWSWIRE) — Verizon recently completed successful trials of Dynamic Spectrum Sharing (DSS) technology in Texas and Minnesota. The trials, conducted in a live network environment, showed effective completion of data sessions with both LTE and 5G NR services running simultaneously over low band spectrum.“The most recent successful trials of our DSS technology demonstrate we are on track to launch 5G Nationwide in 2020,” said Adam Koeppe, Senior Vice President of Technology Planning at Verizon. “DSS will allow us to run 5G technology on the same spectrum bands as LTE without inefficiently wasting spectrum resources. It will complement Verizon’s primary strategy of offering a keenly differentiated 5G Ultra Wideband service on mmWave spectrum which will remain our deployment priority.”Dynamic...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.